Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma

Journal of Proteomics

Volumn 75, Issue 13, 2012, Pages 3898-3913

  Com, Emmanuelle ^a   Clavreul, Anne ^b   Lagarrigue, Mélanie ^a   Michalak, Sophie ^b   Menei, Philippe ^b   Pineau, Charles ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer; Glioblastoma; ICPL; Proteome

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA ENOLASE; BETA ACTIN; CONTACTIN 1; CREATINE KINASE BB; FRUCTOSE BISPHOSPHATE ALDOLASE; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; HEAT SHOCK PROTEIN 90AA1; HEAT SHOCK PROTEIN A8; ISOPROTEIN; MYELIN BASIC PROTEIN; NEUROFILAMENT LIGHT POLYPEPTIDE; PHOSPHOGLYCERATE MUTASE; PROTEIN 14 3 3; PROTEIN 14 3 3GAMMA; PROTEIN ATP1A1; PROTEIN ATP1A2; PROTEIN ATP1A3; PROTEIN YWHAB; PROTEIN YWHAG; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SERUM ALBUMIN; SYNAPSIN I; TUBULIN BETA 4; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; BRAIN BIOPSY; BRAIN REGION; BRAIN TISSUE; CANCER PATIENT; CONTROLLED STUDY; ENERGY METABOLISM; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE CODED PROTEIN LABEL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SYNAPTIC TRANSMISSION; UPREGULATION; VALIDATION PROCESS;

14-3-3 PROTEINS; ACTINS; CARBON ISOTOPES; DEUTERIUM; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HEAT-SHOCK PROTEINS; HUMANS; ISOTOPE LABELING; MASS SPECTROMETRY; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84862677586     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.04.034     Document Type: Article

References (49)

1. Wen P.Y., Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359:492-507.
2. Stupp R., Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):126-128.
3. Giese A., Kucinski T., Knopp U., Goldbrunner R., Hamel W., Mehdorn H.M., et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 2004, 66:351-360.
4. Lefranc F., Brotchi J., Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005, 23:2411-2422.
5. Liang B.C., Thornton A.F., Sandler H.M., Greenberg H.S. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991, 75:559-563.
6. Iacob G., Dinca E.B. Current data and strategy in glioblastoma multiforme. J Med Life 2009, 2:386-393.
7. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
8. Vitucci M., Hayes D.N., Miller C.R. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer 2011, 104:545-553.
9. Carlsson A., Persson O., Ingvarsson J., Widegren B., Salford L., Borrebaeck C.A., et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl 2010, 4:591-602.
10. Niclou S.P., Fack F., Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics 2010, 73:1823-1838.
11. Whittle I.R., Short D.M., Deighton R.F., Kerr L.E., Smith C., McCulloch J. Proteomic analysis of gliomas. Br J Neurosurg 2007, 21:576-582.
12. Deighton R.F., McGregor R., Kemp J., McCulloch J., Whittle I.R. Glioma pathophysiology: insights emerging from proteomics. Brain Pathol 2010, 20:691-703.
13. Ngo T.T., Peng T., Liang X.J., Akeju O., Pastorino S., Zhang W., et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 2007, 99:639-652.
14. Khalil A.A. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 2007, 98:201-213.
15. Melchior K., Tholey A., Heisel S., Keller A., Lenhof H.P., Meese E., et al. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. J Proteome Res 2009, 8:4604-4614.
16. Rajcevic U., Petersen K., Knol J.C., Loos M., Bougnaud S., Klychnikov O., et al. iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics 2009, 8:2595-2612.
17. Seyfried N.T., Huysentruyt L.C., Atwood J.A., Xia Q., Seyfried T.N., Orlando R. Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. Cancer Lett 2008, 263:243-252.
18. Hill J.J., Moreno M.J., Lam J.C., Haqqani A.S., Kelly J.F. Identification of secreted proteins regulated by cAMP in glioblastoma cells using glycopeptide capture and label-free quantification. Proteomics 2009, 9:535-549.
19. Kellermann J. ICPL-isotope-coded protein label. Methods Mol Biol 2008, 424:113-123.
20. Schmidt A., Kellermann J., Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 2005, 5:4-15.
21. Papaioannou M.D., Lagarrigue M., Vejnar C.E., Rolland A.D., Kuhne F., Aubry F., et al. Loss of Dicer in Sertoli cells has a major impact on the testicular proteome of mice. Mol Cell Proteomics 2010, 13:13.
22. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
23. Com E., Evrard B., Roepstorff P., Aubry F., Pineau C. New insights into the rat spermatogonial proteome: identification of 156 additional proteins. Mol Cell Proteomics 2003, 2:248-261.
24. Thiele H., Glandorf J., Hufnagel P. Bioinformatics strategies in life sciences: from data processing and data warehousing to biological knowledge extraction. J Integr Bioinform 2010, 7:141.
25. Thiele H., Glandorf J., Hufnagel P., Körting G., Blüggel M. Managing proteomics data: from generation and data warehousing to central data repository. J Proteomics Bioinf 2008, 1:485-507.
26. Sarioglu H., Brandner S., Jacobsen C., Meindl T., Schmidt A., Kellermann J., et al. Quantitative analysis of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced proteome alterations in 5L rat hepatoma cells using isotope-coded protein labels. Proteomics 2006, 6:2407-2421.
27. Barsnes H., Vizcaino J.A., Eidhammer I., Martens L. PRIDE converter: making proteomics data-sharing easy. Nat Biotechnol 2009, 27:598-599.
28. Chalmel F., Primig M. The Annotation, Mapping, Expression and Network (AMEN) suite of tools for molecular systems biology. BMC Bioinformatics 2008, 9:86.
29. Kersey P.J., Duarte J., Williams A., Karavidopoulou Y., Birney E., Apweiler R. The International Protein Index: an integrated database for proteomics experiments. Proteomics 2004, 4:1985-1988.
30. Park C.K., Jung J.H., Park S.H., Jung H.W., Cho B.K. Multifarious proteomic signatures and regional heterogeneity in glioblastomas. J Neurooncol 2009, 94:31-39.
31. Hobbs S.K., Shi G., Homer R., Harsh G., Atlas S.W., Bednarski M.D. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 2003, 18:530-536.
32. Lottspeich F., Kellermann J. ICPL labeling strategies for proteome research. Methods Mol Biol 2011, 753:55-64.
33. Odreman F., Vindigni M., Gonzales M.L., Niccolini B., Candiano G., Zanotti B., et al. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 2005, 4:698-708.
34. Collet B., Guitton N., Saikali S., Avril T., Pineau C., Hamlat A., et al. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci 2011, 9:16.
35. Morrison D.K. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009, 19:16-23.
36. Boston P.F., Jackson P., Thompson R.J. Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J Neurochem 1982, 38:1475-1482.
37. Cao W.D., Zhang X., Zhang J.N., Yang Z.J., Zhen H.N., Cheng G., et al. Immunocytochemical detection of 14-3-3 in primary nervous system tumors. J Neurooncol 2006, 77:125-130.
38. Yang X., Cao W., Lin H., Zhang W., Lin W., Cao L., et al. Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci 2009, 276:54-59.
39. Liang S., Xu Y., Shen G., Liu Q., Zhao X., Xu Z., et al. Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis 2009, 30:4152-4162.
40. Cao W., Yang X., Zhou J., Teng Z., Cao L., Zhang X., et al. Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis 2010, 15:230-241.
41. Yang X., Zhou J., Cao W., Zhang W., Zhang X., Lin W., et al. 14-3-3zeta positive expression is associated with a poor prognosis in patients with glioblastoma. Neurosurgery 2011, 68:932-938.
42. Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31:164-172.
43. Khalil A.A., Kabapy N.F., Deraz S.F., Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets?. Biochim Biophys Acta 2011, 1816:89-104.
44. Siegelin M.D., Plescia J., Raskett C.M., Gilbert C.A., Ross A.H., Altieri D.C. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol Cancer Ther 2010, 9:1638-1646.
45. Nylandsted J., Wick W., Hirt U.A., Brand K., Rohde M., Leist M., et al. Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res 2002, 62:7139-7142.
46. +-ATPase alpha subunits as new targets in anticancer therapy. Expert Opin Ther Targets 2008, 12:1403-1417.
47. Lefranc F., Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 2008, 10:198-206.
48. Lefranc F., Mijatovic T., Kondo Y., Sauvage S., Roland I., Debeir O., et al. Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 2008, 62:211-221. (discussion 21-2).
49. Chumbalkar V.C., Subhashini C., Dhople V.M., Sundaram C.S., Jagannadham M.V., Kumar K.N., et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005, 5:1167-1177.